Can Tech’s Growth Plans Keep Fueling The Rally? And Losses From California’s Wildfires 1/24/25
CNBC's "Fast Money"
00:00
Weighing the Pros and Cons of Amicretin
This chapter examines the rise in Novo Nordisk's stock following promising trial results for their weight loss injection, amicretin, revealing both optimism and caution amid the early-stage data. It also explores the competitive landscape of the injectable weight loss market and the challenges new entrants face against established pharmaceutical giants.
Transcript
Play full episode
